 Amneal Pharmaceuticals, Inc. NYSE: AMRX Amneal or the Company today announced that it has received Abbreviated New Drug Application ANDA approval from the U.S. Food and Drug Administration FDA for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia. Amneal immediately initiated commercialization activities across all dosages. 